For the treatment of COVID-19
nNanoviricides, Inc., a biotech company headquartered in Shelton, Connecticut, has taken a meaningful leap forward in its mission to combat viral diseases. The company has partnered with a clinical research association to initiate a Phase II clinical trial for its groundbreaking antiviral drug, NV-387. This advancement is a pivotal milestone in the regulatory journey of … Read more